Why the study?
Does flecainide reduce ventricular arrhythmias and improve left ventricular function in a patient with SCN5A-associated MEPPC syndrome?
Case Report (n=1)
No
Does flecainide reduce ventricular arrhythmias and improve left ventricular function in a patient with SCN5A-associated MEPPC syndrome?
Flecainide effectively suppressed refractory ventricular arrhythmias and reversed cardiomyopathy in a patient with MEPPC syndrome driven by a novel SCN5A mutation, challenging guidelines that generally contraindicate class IC agents in structural heart disease.
May support flecainide in refractory SCN5A-MEPPC despite guidelines; hypothesis-generating case that should not yet change practice.
Gain-of-function mutations in the SCN5A gene may cause Multifocal Ectopic Purkinje-related premature Contractions (MEPPC) linked to Purkinje system hyperpolarization and dilated cardiomyopathy. [1] This case highlights the importance of genetic testing in diagnosing arrhythmias and tailoring antiarrhythmic therapy.
No takes yet. Share an insight, caveat, or question.
Turan et al. (2025) conducted a case report in SCN5A-associated MEPPC with dilated cardiomyopathy and electrical storm (n=1). Flecainide was evaluated on Premature ventricular contraction (PVC) burden at 6 weeks (reduction from 50% to 0.3%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: